FAGR Fagron SA

Fagron shareholders approve all voting items AGM

Fagron shareholders approve all voting items AGM

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 12 May 2025 – 7PM CET

Fagron shareholders approve all voting items AGM

Fagron, the leading global player in pharmaceutical compounding, held its annual general shareholders meeting today, where all the voting items were approved.

Resolutions

The annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.35 per share for the fiscal year 2024, the remuneration policy and the appointment of the statutory auditor for the financial years 2025 up to and including 2027. The meeting also approved the proposed reappointment of Ann Desender BV as independent non-executive director until the annual general meeting of the year 2029.

Meeting and meeting documents

All meeting documents for both meetings are available on Fagron’s . The minutes of the meetings will also be made available on the website.

Dividend calendar

The dividend calendar is as follows:

  • Ex-dividend date: 19 May 2025
  • Record date: 20 May 2025
  • Payment date: 21 May 2025



Further information

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment



EN
12/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

Stijn Demeester
  • Stijn Demeester

Fagron/Confident ambitions not yet priced in/BUY

We raise our target price to €26 per share from €22.5 and reiterate our BUY recommendation, as we find Fagron's recent step-up in growth targets is not yet priced in. Given high visibility on organic growth, attractive value and a strengthening track record, Fagron remains on the ING Benelux Favourites list.

Wim Lewi
  • Wim Lewi

Dollar Weakness The impact on our Benelux Coverage

In general, a weaker USD has a negative impact on Benelux stocks, particularly for companies with significant exports to the US. In this note we selected a list of companies with high US export exposure and we examine the potential impact on FY25 earninings. On top of the weak dollar, rising trade tensions or the introduction of tariffs further harm Benelux exporters. As the dollar depreciates against the euro, European goods become costlier for American consumers. At the same time, revenues ear...

 PRESS RELEASE

Fagron increases share capital through exercise subscription rights

Fagron increases share capital through exercise subscription rights Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 85,000 new shares have been issued on 6 June 2025. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 504,303,905.59. The total number of shares with voting rights after the issue amounts to 73,313,904 which is also ...

 PRESS RELEASE

Fagron verhoogt kapitaal door uitoefening van inschrijvingsrechten

Fagron verhoogt kapitaal door uitoefening van inschrijvingsrechten Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 6 juni 2025 – 19:00u. CET Fagron verhoogt kapitaal door uitoefening van inschrijvingsrechten Fagron maakt bekend dat er op 6 juni 2025 85.000 nieuwe aandelen zijn uitgegeven als gevolg van de uitoefening van inschrijvingsrechten. Overeenkomstig de Belgische transparantiewetgeving deelt Fagron mee dat haar maatschappelijk kapitaal na de uitgifte € 504.303.905,59 bedraagt. Het totaal aantal stemrechtverlenende effecten na de uitgifte bedraagt 73.313.904, h...

Guy Sips ... (+11)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update June: Removing Merus, Shurgard and Adyen ...

In this June update, we've made four adjustments to the KBC Securities Dynamic Top Pick List: 1.Merus (Removed – 27 May) was removed following the release of strong interim Phase 2 data at the ASCO 2025 conference. Its lead asset, petosemtamab, in combination with Keytruda, showed a 63% overall response rate in first-line treatment of head and neck cancer—significantly outperforming Keytruda monotherapy. The resulting share price surge validated our investment thesis. 2. Adyen (Removed) has de...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch